The company has gained a lot on the Saas side.
But Abbas Mohaddes was an acclaimed expert in IT-intelligent transportation. He had a long history of being on all the boards,commitees, forums. So the IT side has shoes to fill and the new CEO needs to keep IT rolling. I'm sure he'll have plenty of good adviser there. He knows government because that was his field of study.
The ClearAg and weather analytics has gained an expert at the helm. Iteris needed a Joe Bergera for the expertise there.
This is something to watch. I'm pretty sure the energy at Iteris is ramped right about now.
Abbas Mohaddes - President, CEO
The BASF relationship is initially focus on providing services related to hail forecast and we are in discussion with them to expand that into other services including the soil, surface soil activities, to provide them additional mobile app activities, so that relationship initially is in U.S. and then we intend pursue expansion of that globally.
Quote from 7months ago
Some Republicans are speculating that Boehner’s lame-duck status could free his hand to act on other measures that have bipartisan support but are despised by hard-line conservatives.
Those measures could include an reauthorization of the Export-Import Bank, an extension of the federal debt ceiling, or a long-term highway bill. All of them have been opposed by the same conservatives who have pushed for Boehner’s ouster.
Stopped out. Horrendous. Can't believe how low it went. It went just as bad as it looked last night and it looked UGLY.
Sold everything at a profit while there was still a profit to be had. This was a long squeeze. The worst two days I've had in stocks in at least five years. Absolutely horrible.All due to this one ill behaved stock.
Still have big position in ITI Aris Dysl. Up pretty big on those but but for how long I do not know.
This stock got way ahead of itself. Good long term prospects but I frankly want no big position EVER in this. This was brutal.
I'll find something else. Another sleeper. All biotech got hit today. I'll never buy another strictly biotech again-probably forever.
there has been a bipartisan effort to approve a long-term highway bill. A temporary bill, which passed the House and Senate earlier this year, will expire on Oct. 9.
While the bill is in the hands of the House, Boozman said there are several major issues that surround the topic.
First, the funding in the Highway Trust Fund has been flat for some time with newer fuel efficient vehicles needing less gas. However, a drop in gas prices has caused people to drive more, thus adding more revenue to the fund, Boozman told the group.
When asked a question about funding and the overall federal budget, the Republican lawmaker said the country’s $18 trillion debt has forced congressional officials to push back on discretionary spending, including funding for transportation, defense and federal law enforcement agencies like the FBI.
Meanwhile, entitlement spending has grown with the nation expected to face a $450 billion deficit this year, Boozman said. While there are no earmarks set aside due to a ban on the practice, Arkansas is expected to receive more federal funding under the proposed highway bill.
Secondly, Boozman said officials have been looking for new ways to bring in revenue without raising taxes. It may involve asking states and cities to provide matching funds for projects, he said, as well as building support on the local level for a project before seeking federal help. Also, there is roughly $2 trillion in revenues overseas from U.S. corporations that face a higher tax rate in the U.S. than in other countries, he said.
Stopped out a small portion my long position. Had to puke them out. Disgusting stock but long term prospects are that they will corner a huge market.
Good company, Horrendous nightmare of a stock.
Needs to slaughter some remaining momentum traders, get despicably oversold, make any long who sells regret it and and move on. Bring it on.
Flynn sold. So what!! He sold at $3's. He was wrong. He still has way more than he sold in $5s and he'll sell more in $8's. Guido Neels has 9.6M shares. Management is IN.
Neels will sell when it's doing $.3-.$4 B in revs or more. He knows the science. He knows the product will be accepted. The company is hiring 7 technicians to pack the product as I type. Google it. $15 an hour packers and shippers.That's a lot of product.
This company is a gut-wrench to own shares in. It's in danger of being a trading vehicle for people to use the wild swings for a gamblers rush.
Hate this stock. Hate it. It's a bad buy and hold but right now I'm stuck with it.
There'll be better days.
would be around 5Xrevs. Sounds like the last two deals were for about $2M. Lot of deals in pipeline. Once over $12M market cap of ITI could double.IMO.
Abbas said"Our goal really is within the next few years to have over $40, $50 million worth of software sales"
From CC 10-2014
"A key product that we need to launch that’s scheduled for December, as I indicated, is the sole content and then subsequent to that in March the mobile API. These are two significant products that we expect generating a much larger magnitude in a way of subscription.
"...the next few quarters we would see gradually this revenue coming in from subscription. But it will take us a few quarters before it becomes material."
Was happy. Now disgusted!! Too bad. the company may be worth a lot of money some day but how can you ride the success story out?? DISGUSTED!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I see a job description for 7 people to handle Axogen products:The Nerve Processing Technician will perform debridement and processing, packaging and labeling of human tissue products for surgical transplantation while ensuring compliance with applicable federal, state, and AATB regulations.
SEVEN! But I cannot hold the stock because of the way people dump it. I'm absolutely disgusted.
diagnosis and prediction of ....a mature crop using field-level analysis and forecasting of weather conditions, crop characteristics, and observations and user input of harvest condition states
Also got one approved for measuring traffic flow
Both this week.
Nice call! Looks like it could could go a little higher over next few trading days. Hanging man candle but hang on!! It's been a long time coming. There was a long base. Should run a bit more. News can come at any time so I for one am holding!!
Still loving my ITI too.
I am waiting for the minutes of the meeting to be archived and it should be around 1:50 Pacific time- I believe, the contract for next gen. 511 system was approved. Should get a PR to really confirm this. In any event the company seems on a roll lately. Looking good even without this.
Hopefully he likes having followers at seeking alpha and would not risk losing them by recommending a risky stock like DYSL which had a going concern clause not all that long ago. He seems to have some brainpower and gravitas. Hopefully he is being quite accurate and honest in his assessment of $3 a share, back before the recent large long term contract.
Fundamentals are looking pretty good to me right now. Think it's going higher and it's justified. GLTA!
According to guru focus "Dynasil Corp of America's current price is $1.89. Its book value per share for the quarter that ended in Jun. 2015 was $0.89. Hence, today's P/B Ratio of Dynasil Corp of America is 2.12.
During the past 13 years, the highest P/B Ratio of Dynasil Corp of America was 7.58. The lowest was 0.61. And the median was 1.74"
So, by this one metric, there seems to be some head room all the way to over $6 a share. Such a hypothetical price would mean it would be at a lower multiple than where it traded when it hit 7.58 times B/V.
If you Google Hugh Akston Seeking alpha you'll get to his page there and on the right, click comments. At top of page are all his comments. Click DYSL. He is a Dr. and CFA with 1900+ followers. He pegged intrinsic value at $3 a share. This was back in 5-2014, way before the recent contract which may put $20M into revs and backlog over next few years.
Always best to do your own analysis but I found that $3 a share interesting in context of the recent breakout to higher prices.